ALK-Abelló is the company with the largest number of registered and authorized allergy vaccine products. These vaccines currently come in two forms: injection-based vaccines and drop-based vaccines. ALK-Abelló expects to be the first company to launch a widely available tablet-based vaccine at the end of 2006.

Injection-based vaccines dominate the market in Northern Europe and the USA and account for 59% of ALK-Abelló's revenue. Alutard SQ^® is still the most widely used injection-based product on the market, and around 180,000 people are undergoing treatment with it. The drop-based vaccines are gaining ground in Southern and Central Europe, where they account for more than half and almost a third of the market, respectively. In total, the SLIT products account for 17% of ALK-Abelló's revenue.

Injection-based allergy vaccines:	Subcutaneous immunotherapy (SCIT)
Drop-based allergy vaccines:	Sublingual immunotherapy (SLIT)